MCP-1 -2518 A/G gene polymorphism is associated with blood pressure in ischemic heart disease asymptomatic subjects
11st Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia. pnzptr@gmail.com
Insights
Monocyte chemoattractant protein-1 (MCP-1) gene variants are linked to higher blood pressure in asymptomatic individuals with ischemic heart disease. This MCP-1 polymorphism may indicate increased cardiovascular risk before hypertension onset.
Area of Science:
- Cardiovascular Research
- Genetics
- Inflammation Biology
Background:
- Monocyte chemoattractant protein-1 (MCP-1) is a key chemokine in atherosclerosis and a risk factor for cardiovascular events.
- Previous animal studies suggest a link between MCP-1 gene and salt-sensitive hypertension.
- The association between MCP-1 gene polymorphism and blood pressure in asymptomatic human subjects with ischemic heart disease (IHD) remains understudied.
Purpose of the Study:
- To investigate the association between the MCP-1 -2518 A/G single nucleotide polymorphism (SNP) and arterial blood pressure in asymptomatic subjects with IHD.
- To evaluate inflammatory markers, cardiovascular risk factors, and absolute cardiovascular risk in relation to MCP-1 SNP.
Main Methods:
- Genotyping of the MCP-1 -2518 A/G SNP in 66 hypertensive, asymptomatic IHD subjects.
- Measurement of systolic and diastolic blood pressure.
- Assessment of inflammatory markers, traditional risk factors, and the SCORE system for absolute cardiovascular risk.
Main Results:
- Systolic and diastolic blood pressure were significantly associated with MCP-1 -2518 A/G genotype and allele frequencies.
- Subjects with the mutant G allele or AG/GG genotypes exhibited higher blood pressure levels.
- Individuals with AG/GG genotypes showed increased absolute cardiovascular risk and a trend towards elevated high-sensitivity C-reactive protein (hs-CRP).
- No significant correlation was found between serum MCP-1 levels and blood pressure.
Conclusions:
- The MCP-1 -2518 A/G polymorphism is associated with elevated blood pressure in asymptomatic IHD subjects.
- This MCP-1 variant may contribute to increased cardiovascular risk and potentially precedes hypertension onset.
- Larger cohort studies are required to confirm these findings and their clinical implications.
Abstract:
Monocyte chemoattractant protein-1 (MCP-1), one of the key inflammatory chemokines, plays an important role in the initiation of atherosclerosis, and represents a risk for coronary artery disease and myocardial infarction. A recent animal study showed that MCP-1 gene might be a candidate gene for salt-sensitive hypertension in Dahl salt sensitive rats. This effect has not been yet studied in asymptomatic humans. We tested the MCP-1 -2518 A/G single nucleotide polymorphism (SNP) in 66 hypertensive ischemic heart disease asymptomatic subjects. Inflammatory markers, classic risk factors and absolute cardiovascular risk (SCORE system) were also investigated in these subjects. Our results showed that both, systolic and diastolic values of blood pressure were associated with MCP-1 -2518 A/G SNP at the level of both, genotype and allele frequencies. Subjects with mutant G allele had higher levels of both values of blood pressure, systolic (p = 0.035) and diastolic (p = 0.040) than subjects with allele A. Statistically significantly higher levels of both values of blood pressure, systolic (p = 0.037) and diastolic (p = 0.021) were found also in IHD asymptomatic subjects with AG and GG genotypes. Subjects with AG and GG genotypes had also an increased absolute cardiovascular risk (1.62% vs 3.17%; p = 0.004) and an increasing trend for elevated plasma level of high-sensitive CRP (2.858 vs 2.062 mg/l; p = 0.076). We did not find any significant correlation between the serum level of MCP-1 and blood pressure. To our best knowledge, this is the first study concerning the association between MCP-1 polymorphism and arterial blood pressure in IHD asymptomatic subjects. These results indicate that the expression of MCP-1 may be increased before the onset of hypertension but further observations from larger cohorts are needed to confirm this finding (Tab. 6, Ref. 41).
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Hypertension II: Pathophysiology
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

